Skip to main content
Erschienen in: InFo Hämatologie + Onkologie 4/2017

22.05.2017 | Lungenkarzinome | zertifizierte fortbildung

Lokal fortgeschrittenes NSCLC

Optimale Therapie des nichtkleinzelligen Lungenkarzinoms im Stadium IIIB/C

verfasst von: Hanno M. Specht, Folker Schneller, Hubert Hautmann, Stephanie E. Combs, Dr. med. Dipl. chem. Gregor Habl

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Lungenkrebs gehört trotz der verbesserten Therapieoptionen zu den prognostisch ungünstigen Tumoren. Das lässt sich an einer niedrigen relativen 5-Jahres-Überlebensrate von 21 % bei Frauen und 16 % bei Männern ablesen [1]. Besonders bei Patienten mit lokal fortgeschrittener Erkrankung ist zur optimalen, individualisierten Therapie eine interdisziplinäre Zusammenarbeit zwischen den verschiedenen Fachdisziplinen erforderlich.
Literatur
2.
Zurück zum Zitat Dela Cruz CS et al. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605–44.CrossRefPubMed Dela Cruz CS et al. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605–44.CrossRefPubMed
3.
Zurück zum Zitat Goeckenjan G et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer]. Pneumologie. 2010;64(Suppl 2):e1–164.CrossRefPubMed Goeckenjan G et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer]. Pneumologie. 2010;64(Suppl 2):e1–164.CrossRefPubMed
4.
Zurück zum Zitat Spiro SG et al. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):149S–160S.CrossRefPubMed Spiro SG et al. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):149S–160S.CrossRefPubMed
5.
Zurück zum Zitat Pozo-Rodriguez F et al. Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. J Clin Oncol. 2005;23(33):8348–56.CrossRefPubMed Pozo-Rodriguez F et al. Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. J Clin Oncol. 2005;23(33):8348–56.CrossRefPubMed
6.
Zurück zum Zitat Chen Z et al. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–46.CrossRefPubMed Chen Z et al. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–46.CrossRefPubMed
7.
Zurück zum Zitat Rami-Porta R et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015;10(7):990–1003.CrossRefPubMed Rami-Porta R et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015;10(7):990–1003.CrossRefPubMed
8.
Zurück zum Zitat Eberhardt WE et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2015;10(11):1515–22.CrossRefPubMed Eberhardt WE et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2015;10(11):1515–22.CrossRefPubMed
9.
Zurück zum Zitat Goldstraw P et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39–51.CrossRefPubMed Goldstraw P et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39–51.CrossRefPubMed
10.
Zurück zum Zitat Dillman RO et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323(14):940–5.CrossRefPubMed Dillman RO et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323(14):940–5.CrossRefPubMed
11.
Zurück zum Zitat Schaake-Koning C et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326 8)}:524–30.CrossRefPubMed Schaake-Koning C et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326 8)}:524–30.CrossRefPubMed
12.
Zurück zum Zitat Blanke CD, Johnson DH. Combined modality therapy in non-small cell lung cancer. Curr Opin Oncol. 1995;72):144–9.CrossRefPubMed Blanke CD, Johnson DH. Combined modality therapy in non-small cell lung cancer. Curr Opin Oncol. 1995;72):144–9.CrossRefPubMed
13.
Zurück zum Zitat Marino P et al. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer. 1995;76 4)}:593–601.PubMed Marino P et al. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer. 1995;76 4)}:593–601.PubMed
14.
Zurück zum Zitat Senan S et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(9):953–62.CrossRefPubMed Senan S et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(9):953–62.CrossRefPubMed
15.
Zurück zum Zitat Willner J. et al. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52(2):382–9.CrossRefPubMed Willner J. et al. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52(2):382–9.CrossRefPubMed
16.
Zurück zum Zitat De Ruysscher D et al. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;71(1):132–8.CrossRefPubMed De Ruysscher D et al. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;71(1):132–8.CrossRefPubMed
17.
Zurück zum Zitat Chen M et al. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation? Int J Radiat Oncol Biol Phys. 2006;64(1):120–6.CrossRefPubMed Chen M et al. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation? Int J Radiat Oncol Biol Phys. 2006;64(1):120–6.CrossRefPubMed
18.
Zurück zum Zitat Bradley JD et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99.CrossRefPubMedPubMedCentral Bradley JD et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Bonner JA et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 1999;17 9)}:2681–91.CrossRefPubMed Bonner JA et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 1999;17 9)}:2681–91.CrossRefPubMed
20.
Zurück zum Zitat Schild SE et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;59(4):943–51.CrossRefPubMed Schild SE et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;59(4):943–51.CrossRefPubMed
22.
Zurück zum Zitat Friedel G et al. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol. 2010;28(6):942–8.CrossRefPubMed Friedel G et al. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol. 2010;28(6):942–8.CrossRefPubMed
23.
Zurück zum Zitat Eberhardt WE et al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol. 2015;33(35):4194–201.CrossRefPubMed Eberhardt WE et al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol. 2015;33(35):4194–201.CrossRefPubMed
24.
Zurück zum Zitat Paz-Ares L et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247–55.CrossRefPubMed Paz-Ares L et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247–55.CrossRefPubMed
26.
Zurück zum Zitat Taube JM et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–74.CrossRefPubMedPubMedCentral Taube JM et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–74.CrossRefPubMedPubMedCentral
27.
28.
Zurück zum Zitat Borghaei H et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39.CrossRefPubMed Borghaei H et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39.CrossRefPubMed
29.
Zurück zum Zitat Herbst RS et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.CrossRefPubMed Herbst RS et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.CrossRefPubMed
30.
Zurück zum Zitat Rittmeyer A et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65.CrossRefPubMed Rittmeyer A et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65.CrossRefPubMed
31.
Zurück zum Zitat Reck M et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823–33.CrossRefPubMed Reck M et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823–33.CrossRefPubMed
32.
Zurück zum Zitat Socinski M et al. CheckMate 026: A phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC. Ann Oncol 2016;27(suppl_6):LBA7_PR. Socinski M et al. CheckMate 026: A phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC. Ann Oncol 2016;27(suppl_6):LBA7_PR.
33.
Zurück zum Zitat Specht HM et al. Heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx) - from preclinical studies to a clinical phase II trial. Front Immunol. 2015;6:162.CrossRefPubMedPubMedCentral Specht HM et al. Heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx) - from preclinical studies to a clinical phase II trial. Front Immunol. 2015;6:162.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Pfister K et al. Patient survival by Hsp70 membrane phenotype: association with different routes of metastasis. Cancer. 2007;110(4):926–35.CrossRefPubMed Pfister K et al. Patient survival by Hsp70 membrane phenotype: association with different routes of metastasis. Cancer. 2007;110(4):926–35.CrossRefPubMed
35.
Zurück zum Zitat Huber RM et al. Systemische Therapie des metastasierten nichtkleinzelligen Lungenkarzinoms. In: Manual Tumoren der Lunge und des Mediastinums. 11. Auflage. Aus der Reihe: Die Manuale des Tumorzentrums München. München: W. Zuckerschwerdt Verlag. 2017. Huber RM et al. Systemische Therapie des metastasierten nichtkleinzelligen Lungenkarzinoms. In: Manual Tumoren der Lunge und des Mediastinums. 11. Auflage. Aus der Reihe: Die Manuale des Tumorzentrums München. München: W. Zuckerschwerdt Verlag. 2017.
36.
Zurück zum Zitat Kelly K et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;20;26(15):2450–6.CrossRef Kelly K et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;20;26(15):2450–6.CrossRef
Metadaten
Titel
Lokal fortgeschrittenes NSCLC
Optimale Therapie des nichtkleinzelligen Lungenkarzinoms im Stadium IIIB/C
verfasst von
Hanno M. Specht
Folker Schneller
Hubert Hautmann
Stephanie E. Combs
Dr. med. Dipl. chem. Gregor Habl
Publikationsdatum
22.05.2017
Verlag
Springer Medizin
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 4/2017
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-017-5560-8

Weitere Artikel der Ausgabe 4/2017

InFo Hämatologie + Onkologie 4/2017 Zur Ausgabe

springermedizin aktuell

Step by step zum ePaper